Loading...
•
Jun 30, 2024
Immunocore Q2 2024 Earnings Report
Immunocore reported increased KIMMTRAK sales and advanced its clinical pipeline.
Key Takeaways
Immunocore reported net product sales of $75.3 million for the second quarter of 2024, driven by growth in the US. The company is progressing its clinical trials, including the registrational Phase 3 TEBE-AM trial and the Phase 3 PRISM-MEL-301 trial. Immunocore is also expanding its platform into autoimmune diseases.
KIMMTRAK net product sales reached $75.3 million in Q2 2024, a 32% increase compared to the same period last year.
US growth was driven by increased penetration in the community setting and duration of treatment.
The registrational Phase 3 TEBE-AM trial in previously treated cutaneous melanoma is ongoing, with enrollment expected to complete in 1H 2026.
The registrational Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma started randomization.
Revenue by Segment
Forward Guidance
Immunocore anticipates presenting multiple data read-outs and progressing three Phase 3 trials, with registrational data expected in 2026, 2027 and 2028. The company also plans to advance its new autoimmune and oncology clinical and pre-clinical programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...